Cardiology Service, Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.
Department of Pharmacy, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.
Can J Cardiol. 2017 Oct;33(10):1229-1236. doi: 10.1016/j.cjca.2017.07.479. Epub 2017 Aug 1.
Anterior myocardial infarction (MI) with apical dysfunction is associated with an increased risk of left ventricular thrombus (LVT) formation and systemic embolism (SE). However, the role for prophylactic anticoagulation in current practice is a matter of debate.
We conducted a systematic review of peer-reviewed original articles in either English or French on the benefit of combining anticoagulation with standard therapy for the prevention of LVT/SE after MI by searching PubMed, Ovid/MedLine/Embase, the Cochrane Library, and Google Scholar.
Of 7382 identified records, 14 were retained for analysis. Nine articles addressed anticoagulation for patients not treated with percutaneous coronary intervention (PCI). Another 5 included at least some patients treated with PCI. Only 1 study specifically addressed exclusively a primary PCI population. Some studies showed a benefit for combining anticoagulation with standard therapy in patients not treated with PCI, but results were inconsistent. No evidence of benefit was reported when PCI patients were included and 1 study reported a signal for net harm. There was important interstudy heterogeneity and methodological limitations. Studies were likely individually underpowered.
The available studies of LVT/SE prevention after MI lacked statistical power and are heterogeneous in terms of treatments, revascularization methods, background medical therapy, and study design. We conclude that there is presently no compelling evidence for or against combining anticoagulation with standard therapy for post-MI patients with apical dysfunction after primary PCI, and inconsistent evidence supporting prophylaxis after thrombolysis. An appropriately powered randomized trial is required to answer this clinically relevant question.
前壁心肌梗死伴心尖部功能障碍与左心室血栓(LVT)形成和系统性栓塞(SE)的风险增加相关。然而,目前对于预防性抗凝在实践中的作用存在争议。
我们通过搜索 PubMed、Ovid/MedLine/Embase、Cochrane 图书馆和 Google Scholar,对英文或法文的同行评审原始文献进行了系统性综述,以评估抗凝联合标准治疗在 MI 后预防 LVT/SE 的作用。
在 7382 条记录中,有 14 条被保留用于分析。其中 9 篇文章涉及未接受经皮冠状动脉介入治疗(PCI)的患者的抗凝治疗。另外 5 篇文章包括至少一些接受 PCI 治疗的患者。只有 1 项研究专门针对单纯接受 PCI 的人群。一些研究表明,抗凝联合标准治疗在未接受 PCI 治疗的患者中具有获益,但结果不一致。当包括 PCI 患者时,没有报告获益的证据,并且有 1 项研究报告了净危害信号。研究之间存在重要的异质性和方法学局限性。这些研究可能单独存在效力不足的问题。
目前 MI 后 LVT/SE 预防的研究缺乏统计学效力,并且在治疗、血运重建方法、背景医学治疗和研究设计方面存在异质性。我们得出的结论是,目前对于接受直接 PCI 的 MI 后伴心尖部功能障碍的患者,抗凝联合标准治疗是否有益或有害尚无明确证据,对于溶栓后是否需要预防性抗凝也没有一致的证据。需要一项适当的、有足够效力的随机试验来回答这个具有临床意义的问题。